Sunshine Lake Pharma Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-34
RECRUITING6
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO86%
Delay Index: of 7 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +39.0 months). See all sponsors →
Open Sunshine Lake Pharma Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| HEC585 NCT05060822 |
P2 | Active, not recruiting | Idiopathic Pulmonary Fibrosis | 270 | 2025-07-16 (+29 mo) |
| HEC585 dose A NCT05139719 |
P2 | Recruiting | Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) | 110 | 2026-12 (+40 mo) |
| Mitizodone Phosphate tablets NCT04984512 |
P2/3 | Recruiting | Depressive Disorder, Major | 600 | 2027-07 (+39 mo) |
| Lerotinib NCT04415853 |
P3 | Recruiting | Esophageal Cancer | 416 | 2027-08 (+73 mo) |
| Clifutinib NCT05586074 |
P3 | Recruiting | Leukemia, Acute Myeloid (AML) | 324 | 2027-11-30 (+22 mo) |
| Clifutinib Besylate NCT05133882 |
P1/2 | Recruiting | Acute Myeloid Leukemia, Adult | 133 | 2027-12-31 (+54 mo) |
| HEC53856 tablet NCT07891377 |
P2 | Not yet recruiting | Chemotherapy-induced Anemia; Non-Myeloid Malignancy | 160 | 2028-02 |
| HEC585 NCT07082842 |
P3 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 472 | 2031-01-15 |